New chemo combo shows promise for common throat cancer in southern china
NCT ID NCT04004871
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new combination of chemotherapy drugs (nab-paclitaxel, cisplatin, and fluorouracil) given before standard chemoradiation in 60 people with advanced nasopharyngeal cancer. The goal was to see if this approach could shrink tumors and improve survival. The trial was completed and focused on safety and effectiveness, but it is not a cure and ongoing management is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Sharper radiation boost aims to tackle head and neck cancers that return
- Mouth rinse could ease painful radiation side effects for head and neck cancer patients
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment